Commentary on Characteristics and Outcomes of Posttransplant Infections in the First Year After Receiving a Liver Transplant

Infections remain one of the major causes of morbidity and mortality post liver transplantation. The study by Alpizar-Rivas et al examines post-liver transplant infections during the first year after transplantation. The study addresses a well-recognized but undercharacterized issue post liver transplant. Despite significant advances in surgical techniques, postoperative care, and immunosuppressive therapies, infections continue to account for nearly one-fifth of early postoperative mortality.1 In the study by Alpizar-Rivas et al, more than 50% of liver transplant recipients developed at least one infection within the first year after liver transplantation. These findings were consistent with the 80% incidence of infections reported in European cohorts.2 Authors observed a high incidence of vancomycin‑resistant Enterococcus (VRE) infections, consistent with previously reported studies.3,4 Antimicrobial coverage for VRE is not commonly recommended in existing national surgical site infection treatment or prevention guidelines. These results indicate that VRE coverage is appropriate for surgical prophylaxis and empiric treatment of infections during the early posttransplantation period. This study noted a low incidence of multidrug-resistant (MDR) gram-negative infections and a high incidence of Clostridioides difficile infections. These findings may be attributed to local antimicrobial resistance patterns due to a single-center design in this study. High incidence of Clostridioides difficile infections reflects the need for better antimicrobial stewardship, especially when the rate of MDR infections is low in this patient population. Furthermore, pulmonary infections were infrequent, but when present, they were primarily attributed to nosocomial pathogens such as Pseudomonas and Stenotrophomonas. These findings highlight the continued clinical significance of nosocomial organisms even among patients presenting from home within the first year following liver transplantation. This study identifies several independent predictors of mortality within the first-year post liver transplantation. Chronic obstructive pulmonary disease (COPD) was associated with a 3-fold increased risk of death (RR: ~2.9). Similarly, bacterial infections post liver transplantation were associated with 2.5-fold increased risk for mortality. Return to operative room post liver transplantation was associated with 3-fold increase in mortality. These findings align with prior work showing that surgical complexity, in addition to underlying pulmonary disease and postoperative bacterial infections are associated with increased mortality after liver transplantation.5,6 An interesting observation noted in the study is the association between infections occurring in months 6 to 12 and a more than 2-fold increase in rejection risk. Whether this reflects immune activation, reduction in immunosuppression, or both remains uncertain. However, this observation is consistent with the literature linking infection and alloimmune activity.7,8 The observed link between donor-negative and recipient-positive Cytomegalovirus (CMV) serostatus and rejection in this study corroborates previous findings regarding the relationship between CMV and immune modulation.9 Several practice-relevant conclusions emerge from the current study. One of the most relevant findings is the high incidence of VRE surgical site and intra-abdominal infections in this patient population. This suggests there may be a role for VRE surgical prophylaxis and early implementation of empiric VRE coverage once infection is suspected within the first year following liver transplantation. Although a recent study found that pretransplant VRE screening and surgical prophylaxis for VRE did not decrease the incidence of posttransplant VRE infections.10 This study also emphasizes the need for ongoing vigilance for infections caused by nosocomial pathogens within the first-year post liver transplantation, regardless of whether patients are presenting from home. The inverse relationship between age and rejection risk supports age-tailored immunosuppressive regimens. Because repeat operating room visits are significant predictors of infection and mortality, reducing further surgical exposure may be beneficial; however, failure to address necessary surgical interventions can also increase mortality risk. Such decisions should be made based on each patient’s unique clinical circumstances. Alpizar-Rivas et al provides an important and comprehensive evaluation of infection-related burdens and outcomes in liver transplant recipients. The findings confirm that infection continues to be a primary factor directly impacting mortality in this patient population. Uniquely, it sheds light on less-recognized risk factors, underscoring the potential for a more sophisticated approach towards immunosuppression, infection screening, surgical prophylaxis, and empiric treatment of infections in this patient population. Continued multicenter study designs and prospective research will be essential to refining prophylactic strategies, optimizing empiric therapy, and personalizing immunosuppressive regimens.